Although there are not a few publications about the blocking effect of GP IIb/IIIa in chronic inflammatory diseases other than coronary disease, other integrin families have been under investigation as therapeutic candidates due to their key role in cellular trafficking and activation [33, 34]. The gene discussed is ITGA2B; the disease is coronary artery disorder.